In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

A new trial finds guselkumab is highly effective and well tolerated for moderate to severe scalp psoriasis in individuals ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found ...

Guselkumab and risankizumab for psoriasis have the highest rates of drug survival among biologics measured and a comparable safety profile.

A new study published in the Journal of American Medical Association showed that Guselkumab was highly effective and durable ...

Dr. Zuraw led clinical development of telitacicept across MG, Sjögren’s, SLE, and RA at RemeGen, resulting in multiple ...

Discover a study that demonstrates the effectiveness of guselkumab in treating scalp psoriasis, offering significant symptom ...

Guselkumab improves scalp psoriasis and quality of life in patients with skin of color.

Guselkumab significantly improves psoriasis severity and quality of life compared with placebo in patients with skin of color.

Guselkumab, whether administered every 4 or 8 weeks, demonstrates “significant inhibition” of structural damage in patients with active psoriatic arthritis, according to data presented at the ...

Johnson & Johnson (NYSE:JNJ) on Wednesday reported a second-quarter 2025 adjusted earnings of $2.77 per share, down 1.8% year ...